It is known that spliceosome gene mutations can drive hematological cancers, but there may also be neomorphic mutations at play. In this video, recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, talks about other essential biological pathways that can potentially drive disease if mutated, such as the nuclear export protein XPO1/CRM1. Dr Abdel-Wahab also alludes to a talk regarding co-existing mutations that we can expect at the American Society of Hematology (ASH) 2017 annual meeting.
Neomorphic mutations driving hematological cancers
